Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization

Toshio Naito,1 Yutaro Kaneko2 and Danuta Kozbor1,3

Correspondence
Toshio Naito
naito@med.juntendo.ac.jp

1Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA 19122, USA
2Institute of Immunotherapy and Research for Cancer, Kinki University, Osaka 589-8511, Japan
3Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

Development of a safe and effective vaccine for induction of mucosal immunity to the human immunodeficiency virus (HIV) envelope glycoprotein (Env, gp160) represents the best hope for containing the spread of an HIV epidemic worldwide. The highly attenuated modified vaccinia virus Ankara (MVA) is a laboratory virus well suited as a safe vaccine vector. However, the presence of pre-existing immunity to Vaccinia virus in the adult population represents a hindrance that limits the application of the MVA vector for inducing immunity to HIV antigens. Here, cationic liposomes were covalently attached to the surface of recombinant MVA expressing the HIV-1 strain IIIB Env glycoprotein and β-galactosidase (MVAIIIB/β-gal) using tresylmonomethoxypolyethylene glycol (TMPEG) grafted into a lipid membrane without compromising viral infectivity in vitro and in vivo. The orally administered MVAIIIB/β-gal–TMPEG/liposome complexes were capable of delivering the transgenes to mucosal tissues in mice with pre-existing poxvirus immunity based on β-galactosidase gene expression in intestinal tissues measured 18 h after infection. Importantly, the MVAIIIB/β-gal–TMPEG/liposome complexes enhanced Env-specific cellular and humoral immune responses in the mucosal and systemic tissues after repeated oral immunization of BALB/c mice. This approach may prove useful for induction of protective immunity against infectious diseases and cancer in populations with pre-existing immunity to vaccinia from smallpox vaccination.

INTRODUCTION

Induction of a human immunodeficiency virus (HIV) immune response in mucosal as well as systemic compartments of the immune system is a critical feature of an effective AIDS vaccine. As over 90% of HIV-seropositive individuals acquire the infection via the mucosal surface (Kresina & Mathieson, 1999), this implies that HIV-specific immunity at mucosal sites is critical for the control of infection in many individuals exposed to the virus. Induction of mucosal immunity in the gut has been demonstrated with orally delivered DNA vaccines encapsulated in microparticles made of biologically erodible polymer (Hedley et al., 1998; Jones et al., 1997; Kaneko et al., 2000). Encapsulation not only protects the plasmid DNA from the gastric environment, but, due to the propensity of polymeric spheres for antigen-presenting cell uptake, also increases intracellular delivery of DNA designated to activate immune responses. Separate studies performed with orally administered recombinant viral vaccines have demonstrated that recombinant vaccinia virus (rVV) administered by the oral route generates mucosal and systemic immune responses to the recombinant products as well as antigens of the viral vector (Bender et al., 1996; Gherardi & Esteban, 1999). Independent experiments performed by Belyakov et al. (1998) have demonstrate induction of a mucosal cytotoxic T-lymphotocyte response by intrarectal immunization with MVA expressing the HIV Env glycoprotein and indicated that the non-replicating recombinant MVA may be at least as effective for mucosal immunization as replicating rVV.
A number of more-attenuated VV-derived strains, including MVA (Mayr et al., 1978; Sutter & Moss, 1992, 1995), and strains attenuated by deletion of some non-essential genes such as the NVBAC strain (Tartaglia et al., 1992), have been shown to be safe in healthy as well as in immunocompromised animals. However, there are data suggesting that pre-existing vaccinia immunity, such as that occurring in a large proportion of the adult population because of smallpox vaccination, limits the effectiveness of rVV as a vaccine (Belyakov et al., 1999). A possible solution to this dilemma has been suggested by studies showing that mucosal vaccination could overcome the barrier to rVV immunization caused by pre-existing poxvirus immunity due to the independent compartmentalization of the mucosal versus the systemic immune systems and the asymmetric trafficking of lymphocytes between them (Belyakov et al., 1999). However, this approach has been challenged by studies showing that systemic immunization of mice and monkeys induced both systemic and mucosal immunity in the vaccinated animals (Belyakov et al., 2004; Fuller et al., 2002; Pal et al., 2006). Additional strategies to overcome the barrier of pre-existing immunity to viral vectors including a heterologous prime/boost immunization strategy with DNA vectors or adeno viruses used for priming followed by a booster with MVA (Gurunathan et al., 2000; Schneider et al., 1998) showed some efficacy in animal models. However, each of these approaches would eventually face limitations related to the generation of neutralizing antibodies to multiple vectors in the exposed individuals.

In an effort to overcome the barrier to poxvirus immunization caused by pre-existing immunity to rVV, we have been developing modifications of the recombinant MVA vector expressing the HIV Env glycoprotein and β-galactosidase (β-gal) genes. One such approach involves a covalent attachment of tetracylinomethoxypolyethylene glycol (TMPEG) to the viral capsid through the epsilon-terminal lysine residue (O’Riordan et al., 1999). Previous studies have shown that therapeutic peptides and proteins can be modified with polyethylene glycol (PEG) (Senior et al., 1991) and the half-life of stealth liposomes that carry exterior PEG chains is extended in the human bloodstream (t1/2 of up to 48 h; Zalipsky, 1993). Although the primary advantages involving PEG modification for proteins and peptides include reduced toxicity and enhanced delivery of encapsulated anti-cancer drugs at tumour sites (Lasic, 1998), one of the inherent problems is the potential for reduced bioactivity of the PEG conjugates. Recently, however, it has been shown that many of these limitations can be overcome by biological optimization using TMPEG (O’Riordan et al., 1999).

The present study explores whether cationic liposomes modified with TMPEG are capable of shielding MVAIBIIB/β-gal from poxvirus-neutralizing antibodies in vitro and in vivo. We selected the oral route of immunization, as this method of vaccine delivery has been shown to protect against infection acquired via mucosal surfaces (Chen et al., 1998; Childers et al., 1994; Czerkinsky et al., 1999; Kaneko et al., 2000; McGhee & Mestecky, 1990; Mestecky & Eldridge, 1991). We showed that, after modification using the optimized PEGylation method with cationic liposome complexes, the MVAIBIIB/β-gal-TMPEG/liposome complexes retained infectivity in vitro. Furthermore, the same complexes provided an appreciable level of protection in vivo and elicited Env-specific immune responses in mucosal and systemic tissues of BALB/c mice after repeated oral delivery. These results suggest that the MVAIBIIB/β-gal vector can be modified for effective shielding against pre-existing poxvirus neutralizing antibodies for multiple deliveries.

METHODS

Reagents. TMPEG glycol and PEG were obtained from Sigma. 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), 1,2-dioleoyl-sn-glycer-3-phosphoethanolamine (DOPE) and 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) were purchased from Avanti Polar Lipids. Lentinan (~ 500 kDa) was provided by Ajinomoto Central Laboratories.

Recombinant MVAIBIIB/β-gal. Recombinant MVA expressing the HIV-1 IIB Env glycoprotein and β-gal was generated using the pSC11 shuttle vector (a gift from Dr L. Eisenlohr, Thomas Jefferson University, Philadelphia, PA, USA). The gene encoding the HIV-1 IIB Env glycoprotein was cloned into the Sall and NoR restriction sites of the pSC11 shuttle vector under the control of the VV early/late promoter P7.5 and the β-gal gene was driven by the strong VV late promoter, P11 (Kiszka et al., 2002). The MVAIBIIB/β-gal vector was generated by homologous recombination using plasmid pSC11-env/β-gal and wild-type MVA (a gift from Ds B. Moss and L. Wyatt, Laboratories of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA) as described previously (Wyatt et al., 1995, 1996). The virus was selected by β-Gal screening in the presence of X-Gal or by immunostaining with the Env-specific mAb Chessie 8 (Abacioglou et al., 1994). After five consecutive rounds of plaque purification, recombinant virus was amplified in chicken embryo fibroblasts and purified by centrifugation at 24–40 % sucrose gradients for 50 min at 26 000 g at 4 °C.

Liposome preparation. MVAIBIIB/β-gal-associated liposomes were prepared by dissolving DOTAP, DOPE, DLPC and TMPEG in chloroform at various molar ratios as indicated in Table 1. The lipid monolayer that formed in glass pear-bottomed vials connected to a rotary evaporator (Labconco) was wetted with PBS and liposomes were prepared by intense vortex dispersion and 4 min of sonication. The liposome preparation (800 µl) was mixed with 1 x 107 p.f.u. MVAIBIIB/β-gal in 200 µl PBS, incubated for 30 min at room temperature and sonicated for 1 min. The liposome–MVAIBIIB/β-gal complexes were stabilized by the addition of 100 µg lentinan ml⁻¹ prepared in PBS.

In vitro neutralization assays. Neutralization assays were performed using baby hamster kidney cells (BHK-21; ATCC) and pooled sera from mice immunized four times with the WR strain of non-recombinant VV with an end-point antibody titre against VV of ≥ 1:10 000. For infection, free MVAIBIIB/β-gal or liposome-complexed MVAIBIIB/β-gal (10 p.f.u. ml⁻¹) was combined with pooled immune or control sera (diluted 1:10) for 1 h. The mixtures were then added to a monolayer of BHK cells and incubated for an additional 24 h. The cells were lysed and the level of β-gal was measured using a β-gal reporter gene activity detection kit (Sigma) according to the manufacturer’s instructions. All experiments were performed in triplicate.
Table 1. Effect of different liposomal and TMPEG formulations on MVA IIIB/β-gal infectivity of BHK-21 cells and protection from neutralizing antibodies

<table>
<thead>
<tr>
<th>Compounds*</th>
<th>Molar ratio</th>
<th>Infection (%)†</th>
<th>Protection (%)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>NA</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Liposomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOTAP:DOPE:DLPC</td>
<td>0.3:0.03:0.06</td>
<td>71 ± 2</td>
<td>17 ± 3</td>
</tr>
<tr>
<td>Liposomes/PEG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOTAP:DOPE:DLPC:PEG</td>
<td>0.3:0.03:0.06:0.2</td>
<td>115 ± 4</td>
<td>25 ± 4</td>
</tr>
<tr>
<td>TMPEG</td>
<td>NA</td>
<td>153 ± 2</td>
<td>15 ± 12</td>
</tr>
<tr>
<td>Liposomes/TMPEG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOTAP:DOPE:DLPC:TMPEG</td>
<td>0.3:0.03:0.06:0.1</td>
<td>96 ± 1</td>
<td>65 ± 13</td>
</tr>
<tr>
<td>DOTAP:DOPE:DLPC:TMPEG</td>
<td>0.3:0.03:0.06:0.2</td>
<td>130 ± 6</td>
<td>88 ± 11</td>
</tr>
<tr>
<td>DOTAP:DOPE:DLPC:TMPEG</td>
<td>0.3:0.03:0.06:0.3</td>
<td>115 ± 11</td>
<td>86 ± 12</td>
</tr>
</tbody>
</table>

*MVA IIIB/β-gal-associated liposomes were prepared by dissolving DOTAP, DOPE and DLPC with or without TMPEG in chloroform at various molar ratios. The liposome preparation (800 µl) was mixed with 1 x 10⁷ p.f.u. MVA IIIB/β-gal in 200 µl PBS, incubated for 30 min at room temperature and sonicated prior to infection studies.

†For infection, free MVA IIIB/β-gal or liposome-complexed MVA IIIB/β-gal (10 p.f.u. ml⁻¹) was incubated with a control serum (1:10 dilution of pooled sera from naïve mice) for 1 h. The mixtures were then added to a monolayer of BHK cells and incubated for an additional 24 h. The cells were lysed and the level of β-gal was measured using a β-gal reporter gene activity detection kit. The level of β-gal expression, defined as mU β-gal (mg protein)⁻¹, in cells infected with free MVA IIIB/β-gal in the presence of the control serum (diluted 1:10) was taken as 100%. The percentage of liposome-mediated inhibition of infection with MVA IIIB/β-gal complexed with liposomes or TMPEG was calculated as: (β-gal expression in cells infected with complexed MVA IIIB/β-gal/β-gal expression in cells infected with free MVA IIIB/β-gal) x 100. Results are presented as the means ± SD of at least three independent experiments.

‡Neutralization assays were performed using BHK-21 cells and pooled sera (diluted 1:10) from mice immunized at least three times with the WR strain of non-recombinant VV exhibiting an end-point antibody titre against the VV higher than 1:10000. The level of infection was determined by measuring β-gal expression in cell lysates 24 h after infection. The percentage of liposome-mediated protection of the complexed MVA IIIB/β-gal virus from neutralizing antibodies was determined using a DC reagent kit (Bio-Rad) according to the manufacturer’s protocol and the results were expressed as mU β-gal (mg protein)⁻¹.

NA, Not applicable.

Analyses of fluorescently labelled MVA IIIB/β-gal–TMPEG/liposome complexes in infected cells. MVA IIIB/β-gal (10⁷ p.f.u.) was labelled with 4 µl DII (Vybrant Cell-labelling Solutions; Molecular Probes), washed twice with PBS by centrifugation at 30000 g for 50 min and used for infection of BHK-21 cells in the presence or absence of neutralizing antibodies. In parallel, a liposome film was prepared containing 4 µl DiO dye (Molecular Probes). The DiO-labelled liposomes were washed twice with PBS using a stirred ultrafiltration cell (Millipore) and combined with Di-labelled MVA IIIB/β-gal for infection of BHK-21 cells. After 15 or 30 min of infection, the cells were washed three times with PBS, fixed with 3.7 % paraformaldehyde and mounted for immunofluorescence analyses. The functional integrity of DII- and DiO-labelled MVA IIIB/β-gal–TMPEG/liposome complexes was analysed by confocal microscopy 30 min after infection, as described previously (Gaidarov et al., 1999). Images were collected using a Zeiss Axiovert S100TV microscope with a Zeiss-AuroN (1.25 NA) 63 × objective and a Quantix cooled charge-coupled-device camera containing a Kodak 1400 chip (Photometrics), yielding a size of 0.108 µm in all images. Images were acquired and analysed using IPLab Scientific Imaging software (Scanalytics) and Adobe Photoshop.

Oral administration of liposome-complexed MVA IIIB/β-gal virus to mice with pre-existing poxvirus immunity. BALB/c (H-2b) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and maintained in a specific pathogen-free microisolator environment. Mice (n=6) were immunized orally with 1 x 10⁷ p.f.u. of the WR strain of non-recombinant VV using a 24-gauge feeding needle (Popper & Sons). The immunization was repeated every 3 weeks until antibody titres against VV were higher than 1:10000 and neutralizing antibody titres exceeded 1:50. WR VV-immunized BALB/c mice with pre-existing poxvirus immunity were then orally administered free or TMPEG/liposome-complexed MVA IIIB/β-gal (3 x 10⁷ p.f.u.) virus. Naïve BALB/c mice (n=6) treated with the same preparations of MVA IIIB/β-gal served as controls. The mice were sacrificed 18 h after infection to analyse β-gal gene expression in intestinal tissues using the β-gal reporter gene activity kit (Sigma). The protein concentration in individual samples was determined using a DC reagent kit (Bio-Rad) according to the manufacturer’s protocol and the results were expressed as mU β-gal (mg protein)⁻¹.

Oral vaccination. Groups of BALB/c mice (n=4) were immunized orally with 3 x 10⁷ p.f.u. MVA IIIB/β-gal–TMPEG/liposome complex or MVA IIIB/β-gal and TMPEG/liposomes delivered separately using a 24-gauge feeding needle. Control mice were immunized with wild-type VV and TMPEG/liposomes. Booster immunizations were repeated three times at 4 week intervals. The immunized and control mice were sacrificed 4 weeks after the last immunization to analyse the induction of Env-specific cellular and humoral responses.

Cell purification. Induction of Env-specific cell-mediated immune responses in Peyer’s patches and spleen was analysed 4 weeks after specific immunization. After Peyer’s patches were identified and isolated from the intestinal wall, dead cells and tissue debris were
removed by passing the cells through a cotton/glass wool column (Fisher Scientific) and then layering them on to discontinuous gradients of 75 and 40 % Percoll (Sigma). After centrifugation for 20 min (600 g) at 4 °C, the interface between the two Percoll layers was carefully removed and washed with medium. This procedure resulted in over 95 % viable lymphocytes. Spleen cells were aseptically removed and a single-cell suspension was prepared by gently teasing the cells through sterile screens.

**ELISPOT assay.** The number of CD8+ T lymphocytes secreting gamma interferon (IFN-γ) in the spleen and Peyer’s patches stimulated with a CD8+ T-cell peptide epitope of the HIV Env glycoprotein, 110 (RGPGRAFVTI, aa 315–329; Takahashi et al., 1996) was determined using an ELISPOT assay. Briefly, 96-well nitrocellulose plates (Multiscreen-MAIP; Millipore) were coated with 15 μg rat anti-mouse mAb ml−1 directed against IFN-γ (mAb 785; R&D Systems) in 0.05 M carbonate/bicarbonate buffer (pH 9.6). After overnight incubation at 4 °C, the wells were washed with PBS containing 0.05 % Tween 20 (PBS/Tween 20) and non-specific binding was blocked for 1 h with RPMI 1640 containing 10 % FCS. Cells from immunized mice were resuspended at a concentration of 10^6 cells ml^{-1} and added at various densities to antibody-coated wells in the presence of the Env-specific 110 peptide. After 24 h incubation at 37 °C, the plates were washed six times with PBS containing 0.05 % Tween 20 and incubated for 2 h with 50 μl biotinylated mAb (1 μg ml^{-1}) directed against mouse IFN-γ (mAb 485; R&D Systems). The plates were washed and incubated for 1 h with 50 μl streptavidin-conjugated alkaline phosphatase (SA-5100; Vector Laboratories), diluted 1:1000. After a final wash with PBS, spots were developed with the alkaline phosphatase substrate NBT/BCIP (SK-5400; Vector Laboratories) and counted under a stereomicroscope.

**Anti-Env antibody ELISA.** A direct ELISA assay was used to determine the presence of Env-specific antibodies in the sera of the immunized mice. Ninety-six-well ELISA plates (Nunc) were coated overnight at 4 °C with 100 μl recombinant Env (3 μg ml^{-1}; ImmunoDiagnostics) as described previously (Kaneko et al., 2000). Following a wash with PBS/Tween 20, the wells were blocked for 2 h with 2 % BSA (Sigma) in PBS/Tween 20 at room temperature. Sera were prepared from murine blood samples, serially diluted in PBS/Tween 20 and added to wells. After incubation at room temperature for 1 h, the plates were washed three times and then incubated with a 1:2000 dilution of a peroxidase-conjugated goat anti-mouse Ig (IgG, IgM and IgA; Sigma) in PBS/Tween 20. The plates were washed three times and developed with O-phenylenediamine (0.4 mg ml^{-1}; Sigma) in 0.05 M phosphate/citrate buffer containing 0.03 % sodium perborate (Sigma), stopped with 0.2 M sulfuric acid and analysed at 450 nm with an ELISA plate reader (Dynatech MRX).

**Statistical analyses.** The statistical significance of the difference in Env-specific immune responses between the immunized groups of mice was performed using a two-tailed Student’s t-test assuming equal variance. Data were presented as arithmetic mean ± SD and analysed using the jmp program (SAS Institute) on a Windows-based platform.

**RESULTS**

Protection of MVAIIIB/β-gal from neutralization with poxvirus-specific antibodies by TMPEG/liposome complexes

In our initial experiments, we explored approaches for testing the hypothesis that coating of MVAIIIB/β-gal with liposomes would shield the virus from neutralizing antibodies. We first examined the effect of different formulations of cationic liposomes on the biological activity of MVAIIIB/β-gal by measuring the ability of the virus to infect BHK-21 cells *in vitro*. Infection efficiency was quantified by measuring the level of β-gal gene expression in the infected cultures. The level of infection with free MVAIIIB/β-gal in the presence of sera from unimmunized mice was taken as 100 %. As shown in Table 1, retention of infectivity was largely dependent on the composition of liposomes and the type of liposome conjugation. For example, if MVAIIIB/β-gal was conjugated with cationic liposomes that consisted of DOTAP, DOPE and DLPC (0.3:0.03:0.06), its infectivity was reduced by approximately 30 % compared with that achieved using unconjugated MVAIIIB/β-gal for infection. However, the same liposomes prepared with PEG at a molar ratio of 0.2 preserved infectivity to a greater extent than that observed with the unconjugated virus. The efficiency of infection was further augmented when MVAIIIB/β-gal was complexed with TMPEG or TMPEG/liposomes.

We then evaluated the effectiveness of shielding of the MVAIIIB/β-gal virus from neutralizing antibodies by the different liposomal formulations. Neutralizing assays were performed using BHK-21 cells and pooled sera (diluted 1:10) from mice immunized at least three times with the WR strain of non-recombinant VV with an end-point antibody titre against VV of ≥ 1:10000. The level of infection was determined by measuring β-gal expression in the cell lysates 24 h after infection. Table 1 shows that liposomes alone or associated with PEG provided only a moderate level of protection (17 ± 3 and 25 ± 4 %, respectively). TMPEG had the lowest shielding effect with MVAIIIB/β-gal which is in contrast to results obtained with an adenoviral vector (O’Riordan et al., 1999). However, attaching TMPEG to liposomes provided the highest protection from neutralization, eliciting 88 ± 11 % of the level of infection measured with the untreated MVAIIIB/β-gal and control sera. Protection was also influenced by the concentration of TMPEG, with the highest levels achieved at a molar ratio of 0.2 (Table 1).

**Analysis of fluorescently labelled MVAIIIB/β-gal–TMPEG/liposome complexes during infection**

Considering the possibility that the TMPEG/cationic lipids might have disrupted the virus and that viral DNA was simply being transfected rather than actively infecting the cells, we analysed the infection process with MVAIIIB/β-gal–TMPEG/liposome complexes in BHK-21 cells. The MVAIIIB/β-gal virion and TMPEG/liposomes were labelled separately with the lipophilic dyes DiI and DiO, respectively. BHK-21 cells were then infected with the dual-labelled MVAIIIB/β-gal–TMPEG/liposome complexes in the presence of neutralizing antibodies and the status of infection was analysed by fluorescence microscopy. The results showed that most BHK-21 cells expressing DiI-labelled MVAIIIB/β-gal (red fluorescence; Fig. 1a) on the cell surface were also positive for DiO staining (green fluorescence; Fig. 1b) 15 min after infection, indicating the presence of both virus
and liposomal complexes on the surface of infected cells (Fig. 1c). In contrast, infection was almost completely eliminated if free DiI-labelled MVAIIIB/β-gal was incubated with neutralizing antibodies (Fig. 1d). These results demonstrated that the TMPEG/liposome complex did not compromise the integrity of MVAIIIB/β-gal as the virus retained its infectivity, but it shielded the virus from neutralizing antibodies.

Using confocal microscopy, we next examined the colocalization of DiI-labelled MVAIIIB/β-gal and DiO-labelled TMPEG/liposomes in BHK-21 cells 30 min after infection in the presence of VV-specific antibodies. Fig. 2(a–c) shows that DiI-labelled MVAIIIB/β-gal and DiO-labelled liposomes were similarly distributed within the infected cells. Fluorescence was intense in the trans-Golgi network region, in some endosomal structures and in the cytoplasm near the plasma membrane. These findings indicated that the fluorescently labelled MVAIIIB/β-gal–TMPEG/liposome complexes were capable of infecting BHK-21 cells in the presence of neutralizing antibodies.

**Administration of MVAIIIB/β-gal complexed with TMPEG/liposomes to mice with pre-existing poxvirus immunity**

We investigated whether the TMPEG/liposomes complexed with MVAIIIB/β-gal would be able to deliver the transgenes to mucosal tissues in animals with pre-existing poxvirus immunity. For these experiments, BALB/c mice were first immunized orally with the WR strain of VV (10^7 p.f.u. per mouse) for generation of neutralizing antibodies. The titres of neutralizing antibodies were determined in vitro by measuring the ability of the serially diluted sera from the WR VV-immunized mice to inhibit MVAIIIB/β-gal infection of BHK-21 cells. Immunized mice (n = 6) with serum neutralizing titres ranging from 1:50 to over 1:100, usually detected after the third immunization, received...
3 × 10^7 p.f.u. of MVAIIIB/β-gal orally either as a free virus or complexed with the TMPEG/liposomes. Naïve mice infected with the free or TMPEG/liposome-complexed MVAIIIB/β-gal served as controls. Infection was determined by measuring expression of the β-gal gene in intestinal tissues 18 h after virus delivery. Fig. 3 shows that the level of β-gal expression delivered by free MVAIIIB/β-gal to mice with the pre-existing poxvirus immunity represented approximately 35% of that measured in the naïve mice. In contrast, the MVAIIIB/β-gal vector complexed with TMPEG/liposomes infected the VV-pre-immunized or naïve mice with similar efficiencies. Collectively, these results indicated that the TMPEG/liposome complexes were attached to MVAIIIB/β-gal without compromising the infectivity of the viral vector in vivo.

**Induction of HIV Env-specific cellular and humoral immune responses after repeated immunizations with free or TMPEG/liposome-associated MVAIIIB/β-gal**

The expression of β-gal in intestinal tissues after oral administration of MVAIIIB/β-gal associated with TMPEG/liposomes in mice with pre-existing poxvirus immunity suggested that the MVAIIIB/β-gal virus was protected from neutralizing antibodies in the gastric environment. We next analysed whether the MVAIIIB/β-gal vector complexed with TMPEG/liposomes was capable of inducing HIV Env glycoprotein-specific immune responses in systemic and mucosal tissues of the immunized mice and whether the responses could be increased after multiple vaccinations. BALB/c mice (n = 4) were vaccinated four times with free or TMPEG/liposome complexed-MVAIIIB/β-gal (3 × 10^7 p.f.u. per mouse) at 4 week intervals. An additional group of mice received TMPEG/liposomes and MVAIIIB/β-gal separately to determine whether the virus needed to be complexed with the TMPEG/liposomes prior to in vivo delivery to elicit optimal levels of immune responses. The induction of Env-specific IFN-γ responses in CD8^+ T lymphocytes in spleen and Peyer’s patches was analysed after each immunization by ELISPOT using a CD8^+ T-cell peptide epitope of the Env glycoprotein, I10.

As shown in Fig. 4(a), Env-specific IFN-γ responses in spleen were more than twofold higher after the second immunization in all groups of immunized mice, consistent with the undetectable level of neutralizing antibody responses to MVAIIIB/β-gal after the first immunization. Mice that were immunized with the TMPEG and MVAIIIB/β-gal preparations, delivered separately or as MVAIIIB/β-gal–TMPEG/liposome complexes, had similar responses to

**Fig. 4.** Induction of IFN-γ-producing CD8^+ T-cell responses by repeated immunization with free or TMPEG/liposome-complexed MVAIIIB/β-gal in BALB/c mice. BALB/c mice (n = 4) were immunized with an unconjugated MVAIIIB/β-gal viral vector (vertically hatched bars), TMPEG/liposome-complexed MVAIIIB/β-gal (diagonally hatched bars) or TMPEG/liposomes and MVAIIIB/β-gal delivered separately (filled bars). Control mice (empty bars) were immunized with the wild-type MVA and TMPEG/liposomes. Booster immunizations were carried out every 4 weeks. The frequencies of CD8^+ T cells secreting IFN-γ in cultures established from spleen (a) and Peyer’s patches (b) were determined by ELISPOT assay with the Env-specific peptide I10. Results are shown as the means ± SD of at least three independent experiments. The frequencies of cells secreting IFN-γ were determined by regression analysis from curves generated by plotting numbers of spots versus effector cells. *, P < 0.05; **, P < 0.001.

![Fig. 3.](image-url) Expression of β-gal in intestinal tissues of mice after oral delivery of free MVAIIIB/β-gal (vertically hatched bars) or MVAIIIB/β-gal–TMPEG/liposome complexes (diagonally hatched bars). Naïve BALB/c mice or mice with pre-existing poxvirus immunity (n = 6) received 3 × 10^7 p.f.u. MVAIIIB/β-gal delivered orally either as a free virus or as a complex with the TMPEG/liposomes. The expression of β-gal in intestinal tissues was determined 18 h after virus delivery. Results are presented as the means ± SD of four independent experiments. **, P < 0.001.
those induced by the MVAIIIB/β-gal virus, suggesting that this preparation of TMPEG/liposomes had no adjuvant effect on the level of Env-specific IFN-γ production or the neutralizing antibody response to the viral vector. The profile of the IFN-γ response in Peyer’s patches was similar to that measured in the spleens of immunized mice, although the frequencies of IFN-γ-secreting CD8+ T cells were lower after the first and second immunizations compared with those in splenocytes of the immunized mice. The level of H10 peptide-specific IFN-γ responses in spleen and Peyer’s patches decreased after the third vaccination in mice immunized with the free MVAIIIB/β-gal virus or MVAIIIB/β-gal and TMPEG/liposomes delivered separately. This could be related to the loss of some Env-specific CD8+ effector T cells induced by the first and second immunizations and the ineffective delivery of the env gene by MVAIIIB/β-gal due to generation of neutralizing antibodies that interfered with the infection process. Although we were unable to demonstrate any neutralizing antibodies in faecal washes from immunized mice due to the faecal material being diluted extensively, neutralizing antibodies were detectable after the second immunization at serum dilutions lower than 1:10. In contrast, the numbers of IFN-γ producing CD8+ T lymphocytes in mice immunized with the MVAIIIB/β-gal–TMPEG/liposome complexes remained relatively stable after the third and fourth vaccinations and higher than those measured in the remaining groups of mice (P<0.05).

An ELISA assay used to analyse humoral responses to the Env glycoprotein revealed the presence of Env-specific antibody responses in sera from all groups of MVAIIIB/β-gal-immunized mice after the second immunization, with end-point titres ranging from 1:1300 to 1:1600 (Fig. 5). Consistent with the profile of cellular responses, Env-specific antibody titres increased after the third and fourth immunizations in mice vaccinated with the MVAIIIB/β-gal–TMPEG/liposome complexes and were significantly higher compared with animals vaccinated with free MVAIIIB/β-gal virus or MVAIIIB/β-gal and TMPEG/liposomes delivered separately (P<0.01).

**DISCUSSION**

The primary goal of an effective HIV vaccine is to identify an immunogen that can be formulated in such a way that the vaccine induces a sustained level of anti-HIV immune responses in mucosal and systemic tissues. In this study, we have described a novel approach for delivery of MVAIIIB/β-gal to mice with pre-existing poxvirus immunity. It is becoming increasingly evident that the main concerns that hinder the application of VV-based vectors in AIDS vaccines are related to safety in a potentially immunodeficient human population (Fenner, 1989), as well as the efficacy of the vectors in people previously immunized with a VV vaccine for smallpox (Cooney et al., 1991). These concerns have encouraged the use of avian poxvirus vectors as an alternative delivery system. Although these vectors are considered safer because they do not replicate in mammalian cells and are not affected by previous VV immunity, they appear to be less potent than VV vectors (Hanke et al., 1998; Konishi et al., 1997). The problem of safety has recently been overcome with the introduction of highly attenuated VV strains such as NYVAC (Tartaglia et al., 1992) and MVA (Mayr et al., 1978; Meyer et al., 1991; Sutter & Moss, 1992) as vectors. MVA is replication incompetent in most mammalian cells, but recombinants are as or more immunogenic than replication-competent strains (Belyakov et al., 1998; Hanke et al., 1998). Thus, replication-defective VV vectors appear to have the safety of avian poxvirus vectors without a decrease in immunogenicity. In addition, some recent studies have demonstrated shared modes of protection against poxvirus infection by replication-deficient VVs and conventional smallpox vaccine viruses (Belyakov et al., 2003). These properties, together with the reported protection against lethal VV challenge by a CD8+ T-cell peptide epitope of vaccinia and variola viruses (Snyder et al., 2004), provide a basis for further evaluation of these replication-deficient VVs as safer vaccines against smallpox or complications from VV.

Concern over the use of attenuated VVs as vaccine vectors in the setting of pre-existing immunity to poxvirus has not been resolved fully. Our results show that repeated oral vaccination with MVAIIIB/β-gal covalently attached to TMPEG-modified cationic liposomes induces Env-specific immune responses in VV-immunized mice, suggesting that this strategy may be applicable to individuals with pre-existing immunity to poxvirus and may also be used with other recombinant viral vectors. Although liposomes have been used extensively as a delivery system for a variety of vaccines, the presence of TMPEG/liposomes in the supernatant of VV-infected cells is beneficial for delivery of the viral vector and the finding that the TMPEG/liposome complexes remained relatively stable after the third and fourth vaccinations suggests that the use of TMPEG/liposomes for delivery of the viral vector may be a superior alternative to VV vectors for the development of an effective HIV vaccine.

**Fig. 5.** Induction of Env-specific antibody responses by repeated immunization with free MVAIIIB/β-gal or MVAIIIB/β-gal–TMPEG/liposome complexes. BALB/c mice (n=4) were immunized with the unconjugated MVAIIIB/β-gal viral vector (vertically hatched bars), TMPEG/liposome-complexed MVAIIIB/β-gal (diagonally hatched bars) or TMPEG/liposomes and MVAIIIB/β-gal delivered separately (filled bars). Blood samples were collected 4 weeks after each immunization and ELISA was used to analyse the titre of Env-specific antibody responses in the sera of immunized mice. Titres are shown as the highest serum dilutions with significantly different absorbance values compared with sera from control mice. *, P<0.01; **, P<0.001.
antigens including proteins and peptides, their use in association with viral vectors for oral vaccination remains to be elucidated. Our results indicate that MVA<sub>IIIB/β-gal</sub> complexed with TMPEG/liposomes improves the ability of the recombinant poxviral vector to deliver transgenes repeatedly to mice and also increases the efficacy of gene transfer both in vitro and in vivo. The TMPEG/liposome association with MVA<sub>IIIB/β-gal</sub> preserved the activity of the virus more effectively than viral complexes formed with cationic liposomes or with TMPEG alone, although the infectivity and protection of the modified virus was affected by the concentration of TMPEG, as well as by the lipid component of the liposomes. The modification procedure with TMPEG described here has several advantages over other methods (Francis et al., 1998), as the stable, secondary amine linkage that attaches TMPEG leaves no chemical linker groups on the target molecule (Delgado et al., 1990; Malik et al., 1992). Moreover, in contrast to methods where the linkers compromise the surface charge, the nitrogen atom to which the TMPEG chains is attached results in better conservation of the surface charge than many indirect linkages (O’Riordan et al., 1999). The major additional advantages of the TMPEG method are that protein coupling occurs under physiological conditions (Delgado et al., 1990) and that the presence of TMPEG on the surface of liposomes inhibits aggregation (Harasym et al., 1995). TMPEG has also been coupled to proteins and liposomes to prolong their circulation, as it acts as a surface barrier to plasma factors that otherwise bind to liposomes in the blood and accelerate vesicle removal (Fuertges & Abuchowski, 1990; Senior et al., 1991). Similarly, incorporating hydrophilic TMPEG molecules in liposomes may provide a steric barrier that inhibits the association of serum proteins, including neutralizing antibodies, with the virion. Furthermore, the direct association of cationic liposomes with the recombinant viral vector may add an additional adjuvant property to the complex, as cationic liposomes have been widely applied to enhance immune responses (Bangham, 1963; Gregoriadis & Ryman, 1972; Ishii et al., 1997; Wierzbicki et al., 2002). In our studies, however, we were unable to detect any adjuvant effect of the TMPEG/liposomal complex on the induction of Env-specific immune responses in MVA<sub>IIIB/β-gal</sub>-immunized mice. As the adjuvant properties of liposomes may be dependent on their lipid compositions, additional experiments are required to promote beneficial immune responses induced by the MVA<sub>IIIB/β-gal</sub>-TMPEG/liposome vaccine. This strategy may also be useful for the delivery of replication-attenuated recombinant viruses, as their association with liposomes may improve viral dissemination in vivo or protect the viral vector from the acidic environment of the gastrointestinal tract.

The important feature of our approach is versatility, as all viral vectors could be susceptible to TMPEG modification alone or in association with liposomes, regardless of the transgene contained within the vector. Although the condition of TMPEG modification and the composition of liposomes may differ for each viral vector, our approach offers a relatively safe solution to the issue of vector neutralization. An additional advantage of this delivery system is that liposomes can be used as carriers for adjuvant delivery, concomitant with the immunogen at the time of vaccination. In summary, our study describes the potential of oral vaccines with replication-attenuated viral vectors for repeated induction and augmentation of HIV Env-specific cellular and humoral responses. Although a successful HIV vaccine is likely to require the incorporation of other HIV antigens together with co-stimulatory molecules or immunomodulatory cytokines that amplify antigen presentation, our results offer a strategy that can facilitate the development of prophylactic and therapeutic AIDS vaccines.

ACKNOWLEDGEMENTS

We are grateful to Drs Bernard Moss and Patricia Earl for reagents. We acknowledge the assistance of the Confocal Microscopy Facility at Thomas Jefferson University in Philadelphia, PA, USA. This study was supported by research grants from the National Institute of Allergy & Infectious Diseases to Dr Danuta Kozbor (R21AI060375), the Japan Health Sciences Foundation and funds to commemorate Dr Goro Chihara’s research activity. T. N. was a Research Scholar of the Japan Health Sciences Foundation.

REFERENCES


Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA vaccines with poxviral vectors.


